Press Release

Changes of Representative Directors and Directors

Tokyo, April 27, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "the Company") today announced that at a meeting of its Board of Directors held today, it decided changes of Representative Directors and Directors as stated below. These changes are subject to approval at the Ordinary General Meeting of Shareholders to be held on June 19, 2017 and decision at the Board of Directors meeting scheduled for the same day.

1. Changes of Representative Directors

(New Representative Director candidate)

Kenji Yasukawa
(New) Representative Director, Executive Vice President
(Current) Senior Corporate Executive, Senior Vice President, CSTO & CCO

CSTO: Chief Strategy Officer
CCO: Chief Commercial Officer

(Representative Director to be retired)

Yoshirou Miyokawa
(Current) Representative Director, Executive Vice President

- Effective date of changes: June 19, 2017
- Reason for changes: Those changes are decided in order to pursue Astellas' growth strategies more vigorously by new leader.

- **Curriculum Vitae of new Representative Director candidate**

Name: Kenji Yasukawa
Date of Birth: June 7, 1960
Place of Birth: Tokyo

-Education

March 1986	University of Tokyo, Master of Science, Agriculture
July 2001	Showa University Graduate School of Pharmaceutical Sciences, Japan, Ph.D. in Pharmaceutical Sciences

-Carrier History

April 1986	Joined the Company (former Yamanouchi Pharmaceutical Co., Ltd.)
April 2005	Vice President, Project Management, Urology, the Company
June 2010	Corporate Executive, Therapeutic Area Head, Urology, Astellas Pharma Europe B.V., the Company
October 2010	Corporate Executive, Therapeutic Area Head, Urology, Astellas Pharma Global Development, Inc., the Company
April 2011	Corporate Executive, Vice President, Product & Portfolio Strategy, the Company
April 2012	Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company
June 2012	Senior Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company
April 2017	Senior Corporate Executive, Senior Vice President, Chief Strategy Officer and Chief Commercial Officer, the Company

Ownership of shares: 11,315 shares (as of March 31, 2017)

2. New Candidates of Directors

Director	Kenji Yasukawa
Outside Director	Mamoru Sekiyama
Outside Director	Keiko Yamagami

3. Directors to be retired

Director	Yoshirou Miyokawa
Outside Director	Yutaka Kase
Outside Director	Hironobu Yasuda

(Reference)

Curriculum Vitae of new Director candidates

Name: Mamoru Sekiyama
Date of Birth: August 14, 1949

-Carrier History

April 1974	Joined Marubeni Corporation
April 1997	General Manager, Power Project Dept.-I, Marubeni Corporation
April 1998	General Manager, Power Project Dept.-III, Marubeni Corporation
April 1999	Deputy General Manager, Power Project Div.; General Manager, Power Project Dept. I, Marubeni Corporation
April 2001	Senior Operating Officer, Utility Infrastructure Div.; General Manager, Overseas Power Project Dept., Marubeni Corporation
April 2002	Corporate Vice President, Chief Operating Officer, Plant, Power & Infrastructure Div., Marubeni Corporation
April 2005	Corporate Senior Vice President, Chief Operating Officer, Plant, Power & Infrastructure Projects Div., Marubeni Corporation
June 2006	Corporate Senior Vice President, Member of the Board, Marubeni Corporation
April 2007	Corporate Executive Vice President, Member of the Board, Marubeni Corporation
April 2009	Senior Executive Vice President, Member of the Board, Marubeni Corporation
April 2013	Vice Chairman, Marubeni Corporation
April 2015	Corporate Adviser, Marubeni Corporation (present post)
	Chairman, Marubeni Power Systems Corporation

Name: Keiko Yamagami
Date of Birth: March 22, 1961

-Carrier History

April 1987	Public Prosecutor, Yokohama District Public Prosecutors Office
April 2002	Coordinator, the Legislative Division, Criminal Affairs Bureau, Ministry of Justice
January 2005	Counselor, the Legislative Division, Criminal Affairs Bureau, Ministry of Justice
August 2005	Public Prosecutor, Supreme Public Prosecutors Office
August 2007	Deputy Director of Public Peace Department, Tokyo District Public Prosecutors Office
July 2008	Deputy Director of Trial Department, Tokyo District Public Prosecutors Office
April 2009	Trial Director, Yokohama District Public Prosecutors Office
April 2010	Registered as an attorney-at-law (Dai-ichi Tokyo Bar Association) Lawyer honorary member, Tokyo Seiwa Law Office (present post)

4. The Board of Directors and the Audit & Supervisory Board as from June 19, 2017 (planned full members)

Members of the Board of Directors

Yoshihiko Hatanaka (Representative Director, President and Chief Executive Officer)

Kenji Yasukawa (Representative Director, Executive Vice President)

Etsuko Okajima (Outside Director)

Yoshiharu Aizawa (Outside Director)

Mamoru Sekiyama (Outside Director)

Keiko Yamagami (Outside Director)

Members of the Audit & Supervisory Board

Tomokazu Fujisawa (Audit & Supervisory Board Member)

Hiroko Sakai (Audit & Supervisory Board Member)

Toshiko Oka (Outside Audit & Supervisory Board Member)

Hitoshi Kanamori (Outside Audit & Supervisory Board Member)

Noriyuki Uematsu (Outside Audit & Supervisory Board Member)

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers

in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473